Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib by Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi

Subjects: Get full text

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo

Subjects: Get full text

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy by Hironori Ochi, Masayuki Kurosaki, Takaaki Tanaka, Nobuharu Tamaki, Kaoru Tsuchiya, Yutaka Yasui, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Takehiro Akahane, Eisuke Okamoto, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Namiki Izumi

Subjects: Get full text

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors by Xin Y, Liu N, Peng G, Huang X, Cao X, Zhou X

Subjects: “…lenvatinib…”
Get full text

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver by Indra Radek, Jelínková Sandra, Kollárová Katarína, Zahumenská Petra, Dvořák Josef, Dušková Šárka, Dračínská Helena

Subjects: “…lenvatinib…”
Get full text

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study by Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu

Subjects: Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

Subjects: Get full text

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice by V. V. Petkau, A. V. Sultanbaev, K. V. Menshikov, A. S. Antipin, M. V. Volkonsky, V. M. Filippova, Yu. V. Vasilyeva, A. A. Tarkhanov, M. R. Mukhitova, M. Zh. Murzalina, A. R. Safarova

Subjects: Get full text

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus by Li X, Cao K, Fu Z, Chen X, Zhong J, Liu L, Ding N, Zhang X, Qu Z, Zhu L, Zhai J

Subjects: Get full text

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling by Xindong Wei, Anfeng Si, Shuai Zhao, Yi Fu, Jilei Li, Kedeerya Aishanjiang, Yujie Ma, Chang Yu, Bo Yu, Chunhong Cui, Hui Wang, Xianming Kong, Shibo Li, Xiaoni Kong, Ying Tong, Hailong Wu

Subjects: Get full text

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis by Lingling Zhao, Cheng Xu, Jiewen Deng, Yang Ni

Subjects: Get full text